X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA SUVEN LIFE SHASUN PHARMA/
SUVEN LIFE
 
P/E (TTM) x 123.9 17.2 718.4% View Chart
P/BV x 8.5 3.6 239.7% View Chart
Dividend Yield % 0.2 0.6 36.4%  

Financials

 SHASUN PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
SUVEN LIFE
Mar-18
SHASUN PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs94251 37.6%   
Low Rs46155 29.4%   
Sales per share (Unadj.) Rs214.249.1 436.0%  
Earnings per share (Unadj.) Rs5.39.7 54.9%  
Cash flow per share (Unadj.) Rs15.811.4 138.9%  
Dividends per share (Unadj.) Rs1.001.50 66.7%  
Dividend yield (eoy) %1.40.7 193.5%  
Book value per share (Unadj.) Rs53.360.3 88.5%  
Shares outstanding (eoy) m56.62127.28 44.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.1 7.9%   
Avg P/E ratio x13.120.9 62.7%  
P/CF ratio (eoy) x4.417.8 24.8%  
Price / Book Value ratio x1.33.4 38.9%  
Dividend payout %18.715.4 121.4%   
Avg Mkt Cap Rs m3,95825,825 15.3%   
No. of employees `000NA1.1 0.0%   
Total wages/salary Rs m2,164613 353.1%   
Avg. sales/employee Rs ThNM5,832.6-  
Avg. wages/employee Rs ThNM571.5-  
Avg. net profit/employee Rs ThNM1,153.8-  
INCOME DATA
Net Sales Rs m12,1276,253 193.9%  
Other income Rs m229233 98.6%   
Total revenues Rs m12,3566,485 190.5%   
Gross profit Rs m1,0091,982 50.9%  
Depreciation Rs m594213 278.6%   
Interest Rs m41546 896.5%   
Profit before tax Rs m2301,955 11.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73718 -10.1%   
Profit after tax Rs m3021,237 24.4%  
Gross profit margin %8.331.7 26.3%  
Effective tax rate %-31.736.7 -86.2%   
Net profit margin %2.519.8 12.6%  
BALANCE SHEET DATA
Current assets Rs m6,8845,622 122.4%   
Current liabilities Rs m8,4561,168 724.2%   
Net working cap to sales %-13.071.2 -18.2%  
Current ratio x0.84.8 16.9%  
Inventory Days Days6281 75.7%  
Debtors Days Days10836 299.4%  
Net fixed assets Rs m4,9703,325 149.5%   
Share capital Rs m113127 89.0%   
"Free" reserves Rs m2,8757,547 38.1%   
Net worth Rs m3,0207,674 39.4%   
Long term debt Rs m1,81714 13,074.8%   
Total assets Rs m13,3479,135 146.1%  
Interest coverage x1.643.2 3.6%   
Debt to equity ratio x0.60 33,222.1%  
Sales to assets ratio x0.90.7 132.7%   
Return on assets %5.414.0 38.3%  
Return on equity %10.016.1 62.1%  
Return on capital %13.326.0 51.2%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,8435,066 115.3%   
Fx outflow Rs m2,1732,001 108.6%   
Net fx Rs m3,6693,065 119.7%   
CASH FLOW
From Operations Rs m398699 56.8%  
From Investments Rs m-1,635-6 26,803.3%  
From Financial Activity Rs m1,309-577 -226.8%  
Net Cashflow Rs m71116 61.2%  

Share Holding

Indian Promoters % 39.2 63.4 61.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 0.0 -  
FIIs % 17.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 36.5 108.5%  
Shareholders   20,750 37,287 55.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  WYETH LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Depreciating Rupee; IPO Buzz and Top Cues in Focus Today(Pre-Open)

Indian share markets ended lower yesterday with banking stocks and metal stocks leading the losses. At the closing bell, the BSE Sensex ended down by 188 points (0.5%).

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

SUVEN LIFE Announces Quarterly Results (4QFY18); Net Profit Up 56.0% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SUVEN LIFE has posted a net profit of Rs 625 m (up 56.0% YoY). Sales on the other hand came in at Rs 2 bn (up 18.6% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS